Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing ...
Dec 9, 2022
0
390
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies ...
Nov 26, 2020
0
92
Peter Mac researchers have developed a new approach to chimeric antigen receptor (CAR) T-cell therapy which has proven effective in fighting solid cancer tumors.
Apr 7, 2023
0
94
Research led by the Dana Farber Cancer Institute, Massachusetts, performed a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial. In the paper, "Risk of Short-Term Prostate-Specific Antigen Recurrence and ...
In 2010, I wrote a free book on prostate cancer testing with two colleagues, Alex Barratt (an epidemiologist) and Martin Stockler (a clinical oncologist), Let sleeping dogs lie? What men should know before getting tested ...
Aug 9, 2017
0
20
Conventional wisdom has it that high levels of testosterone help prostate cancers grow.
Jan 7, 2015
0
50
A promising new way to treat some types of cancer is to program the patient's own T cells to destroy the cancerous cells. This approach, termed CAR-T cell therapy, is now used to combat some types of leukemia, but so far ...
Jul 11, 2019
0
256
Dr. Christopher E. Rudd, a researcher at the Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) and Université de Montréal, has discovered a new cell therapy approach that boosts the immune response of T lymphocytes ...
Oct 25, 2019
0
4
UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for "off-the-shelf" cell therapy to treat challenging cancers.
Nov 8, 2023
0
84
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
